Psilocybin

Generic Name: Psilocybin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₇N_₂O_₄P

CAS Number: 520-52-5

Unique Ingredient Identifier: 2RV7212BP0

Background: Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Optimi Health & ATMA Receive No Objection Letter from Health Canada for Phase 2 Clinical Trial

Optimi Health Corp. received Health Canada's approval for a Phase 2 clinical trial using their GMP natural psilocybin extract capsules to study Major Depressive Disorder in 200 participants, focusing on frontline mental healthcare workers affected by COVID-19. The trial aims to assess the safety, efficacy, and therapeutic potential of psilocybin, potentially integrating it into clinical practice in Canada.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy